UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
Washington,
D.C. 20549
FORM
8-K
CURRENT
REPORT
Pursuant
to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of
Report (Date of earliest event reported): December 6, 2010
Brainstorm
Cell Therapeutics Inc.
(Exact
name of registrant as specified in its charter)
|
Delaware
|
333-61610
|
20-8133057
|
||||
|
(State
or other jurisdiction of incorporation)
|
(Commission
File No.)
|
(IRS
Employer Identification No.)
|
|
110
East 59th
Street
|
|
|
New
York, New York
|
10022
|
|
(Address
of principal executive offices)
|
(Zip
Code)
|
(212)
557-9000
(Registrant’s
telephone number, including area code)
N/A
(Former
name or former address, if changed since last report)
Check the
appropriate box below if the Form 8-K filing is intended to simultaneously
satisfy the filing obligation of the registrant under any of the following
provisions:
o Written communications
pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
o Soliciting material
pursuant to Rule 14a-12 under the Exchange Act (17 CFR
240.14a-12)
o Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR
240.14d-2(b))
o Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR
240.13e-4(c))
Item 5.02
Departure of Directors or Certain Officers; Election of Directors; Appointment
of Certain Officers; Compensatory Arrangements of Certain Officers.
On
December 6, 2010, BrainStorm Cell Therapeutics, Inc.’s Chief Executive Officer
and a member of the board of directors, Abraham (Rami) Efrati, tendered his
resignation to the Company in order to pursue other
opportunities. Mr. Efrati’s resignation will be effective as of on or
around February 28, 2011. The registrant is currently searching for a
successor to Mr. Efrati. The registrant owes Mr. Efrati approximately
1 million NIS (approximately US$270,000) for salary payments that were deferred
in past years to help the registrant during times of financial difficulty. The
parties are currently negotiating the method of such payment to Mr.
Efrati. Other than the above payments owed, Mr. Efrati did not have any
disagreements with the registrant.
Pursuant
to the requirements of the Securities Exchange Act of 1934, the registrant has
duly caused this report to be signed on its behalf by the undersigned hereunto
duly authorized.
|
December
10, 2010
|
Brainstorm
Cell Therapeutics Inc.
|
||
|
By:
|
/s/
Chaim Lebovits
|
||
|
Chaim
Lebovits
|
|||
|
President
|
|||